Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.

Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.

While the unjust enrichment claim against Ultragenyx uses the same argument the estate of Henrietta Lacks employed against Thermo Fisher, resulting in a settlement earlier this month, one big difference between the cases is that Ultragenyx does not yet have a commercial product that relies on the HeLa cells.

After settling for an undisclosed sum with Thermo Fisher, the estate of Henrietta Lacks signals it will initiate further lawsuits against defendants alleged to have unjustly profited from the use of HeLa cells.